Artemisinin-based combination therapies: A vital tool in efforts to eliminate malaria

Nature Reviews Microbiology

Volumn 7, Issue 12, 2009, Pages 864-874

  Eastman, Richard T ^a   Fidock, David A ^a  

^a Hammer Health Sciences Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISINIC ACID; ARTEMISININ DERIVATIVE; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; CYTOCHROME P450; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; PIPERAQUINE; PYRIMETHAMINE; PYRIMETHAMINE SULFADIAZINE; PYRONARIDINE; QUININE; SESQUITERPENE LACTONE DERIVATIVE; SULFADOXINE;

AGRANULOCYTOSIS; ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; BIRTH DEFECT; CLINICAL TRIAL; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG COST; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG ISOLATION; DRUG RESEARCH; DRUG SYNTHESIS; EMBRYOTOXICITY; FETOTOXICITY; HEPATITIS; HUMAN; MALARIA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; DRUG COMBINATIONS; DRUG DESIGN; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; MALARIA; MALARIA, FALCIPARUM; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; POPULATION DENSITY; PYRIMETHAMINE; SULFADOXINE; TRAVEL; TREATMENT OUTCOME;

PLASMODIUM FALCIPARUM; PLASMODIUM PARASITES;

EID: 70449732094     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro2239     Document Type: Review

References (140)

1. Wellems, T. E. & Plowe, C. V. Chloroquine-resistant malaria. J. Infect. Dis. 184, 770-776 (2001).
2. Gregson, A. & Plowe, C. V. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol. Rev. 57, 117-145 (2005).
3. Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H. & Meshnick, S. R. Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2, 209-218 (2002).
4. Snow, R. W., Guerra, C. A., Noor, A. M., Myint, H. Y. & Hay, S. I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434, 214-217 (2005).
5. Talisuna, A. O., Okello, P. E., Erhart, A., Coosemans, M. & D'Alessandro, U. Intensity of malaria transmission and the spread of Plasmodium falciparum resistant malaria: A review of epidemiologic field evidence. Am. J. Trop. Med. Hyg. 77, 170-180 (2007).
6. Feachem, R. & Sabot, O. A new global malaria eradication strategy. Lancet 371, 1633-1635 (2008).
7. Jiang, J. B., Li, G. Q., Guo, X. B., Kong, Y. C. & Arnold, K. Antimalarial activity of mefloquine and qinghaosu. Lancet 2, 285-288 (1982).
8. White, N. J. Qinghaosu (artemisinin): The price of success. Science 320, 330-334 (2008).
9. Ro, D. K. et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440, 940-943 (2006).
10. German, P. I. & Aweeka, F. T. Clinical pharmacology of artemisinin-based combination therapies. Clin. Pharmacokinet. 47, 91-102 (2008).
11. Golenser, J., Waknine, J. H., Krugliak, M., Hunt, N. H. & Grau, G. E. Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol. 36, 1427-1441 (2006).
12. Hartwig, C. L. et al. Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochem. Pharmacol. 77, 322-336 (2009).
13. Robert, A., Benoit-Vical, F., Claparols, C. & Meunier, B. The antimalarial drug artemisinin alkylates heme in infected mice. Proc. Natl Acad. Sci. USA 102, 13676-13680 (2005).
14. Bousejra-El Garah, F., Claparols, C., Benoit-Vical, F., Meunier, B. & Robert, A. The antimalarial trioxaquine DU1301 alkylates heme in malaria-infected mice. Antimicrob. Agents Chemother. 52, 2966-2969 (2008).
15. Creek, D. J. et al. Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials. Antimicrob. Agents Chemother. 52, 1291-1296 (2008).
16. Creek, D. J. et al. Stability of peroxide antimalarials in the presence of human hemoglobin. Antimicrob. Agents Chemother. 53 3496-3500 (2009).
17. Krungkrai, S. R. & Yuthavong, Y. The antimalarial action on Plasmodium falciparum of qinghaosu and artesunate in combination with agents which modulate oxidant stress. Trans. R. Soc. Trop. Med. Hyg. 81, 710-714 (1987).
18. Asawamahasakda, W., Ittarat, I., Pu, Y. M., Ziffer, H. & Meshnick, S. R. Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob. Agents Chemother. 38, 1854-1858 (1994).
19. Kannan, R., Kumar, K., Sahal, D., Kukreti, S. & Chauhan, V. S. Reaction of artemisinin with haemoglobin: Implications for antimalarial activity. Biochem. J. 385, 409-418 (2005).
20. Wu, Y. How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. Acc. Chem. Res. 35, 255-259 (2002).
21. Stocks, P. A. et al. Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs. Angew. Chem. Int. Edn Engl. 46, 6278-6283 (2007).
22. del Pilar Crespo, M. et al. Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. Antimicrob. Agents Chemother. 52, 98-109 (2008).
23. 3H]-dihydroartemisinin translationally controlled tumor protein (TCTP) adducts from Plasmodium falciparum-infected erythrocytes by using anti-TCTP antibodies. Antimicrob. Agents Chemother. 45, 2397-2399 (2001).
24. Olliaro, P. L., Haynes, R. K., Meunier, B. & Yuthavong, Y. Possible modes of action of the artemisinin-type compounds. Trends Parasitol. 17, 122-126 (2001).
25. Eckstein-Ludwig, U. et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424, 957-961 (2003).
26. Jambou, R. et al. Resistance of Plasmodium falciparum field isolates to in vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366, 1960-1963 (2005).
27. 2+ -ATPase orthologue of Plasmodium falciparum (PfATP6). Infect. Genet. Evol. 8, 340-345 (2008).
28. Valderramos, S. G. & Fidock, D. A. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol. Sci. 27, 594-601 (2006).
29. Price, R. N. et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364, 438-447 (2004).
30. Sidhu, A. B. et al. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. 194, 528-535 (2006).
31. Raj, D. K. et al. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J. Biol. Chem. 284, 7687-7696 (2009).
32. Noedl, H., Socheat, D. & Satimai, W. Artemisinin-resistant malaria in Asia. N. Engl. J. Med. 361, 540-541 (2009).
33. Dondorp, A. M. et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455-467 (2009).
34. Wootton, J. C. et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418, 320-323 (2002).
35. Roper, C. et al. Intercontinental spread of pyrimethamine-resistant malaria. Science 305, 1124 (2004).
36. Klein, E. Y., Smith, D. L., Boni, M. F. & Laxminarayan, R. Clinically immune hosts as a refuge for drug-sensitive malaria parasites. Malar. J. 7, 67 (2008).
37. Rathod, P. K., McErlean, T. & Lee, P.-C. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc. Natl Acad. Sci. USA 94, 9389-9393 (1997).
38. Ekland, E. H. & Fidock, D. A. Advances in understanding the genetic basis of antimalarial drug resistance. Curr. Opin. Microbiol. 10, 363-370 (2007).
39. Dharia, N. V. et al. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol. 10, R21 (2009).
40. Kozarewa, I. et al. Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G+CJ)-biased genomes. Nature Methods 6, 291-295 (2009).
41. 2+ ATPase), tctp, mdr1, and cg10. Antimicrob. Agents Chemother. 50, 480-489 (2006).
42. Hunt, P. et al. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquineresistant rodent malaria parasites. Mol. Microbiol. 65, 27-40 (2007).
43. Woodrow, C. J. & Krishna, S. Antimalarial drugs: Recent advances in molecular determinants of resistance and their clinical significance. Cell Mol. Life Sci. 63, 1586-1596 (2006).
44. Bukirwa, H. & Critchley, J. Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria. Cochrane Database Syst. Rev. 2006, CD004966 (2006).
45. Sullivan, D. J., Jr, Matile, H., Ridley, R. G. & Goldberg, D. E. A common mechanism for blockade of heme polymerization by antimalarial quinolines. J. Biol. Chem. 273, 31103-31107 (1998).
46. Rohrbach, P. et al. Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. EMBO J. 25, 3000-3011 (2006).
47. Alker, A. P. et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am. J. Trop. Med. Hyg. 76, 641-647 (2007).
48. Nosten, F. et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: A prospective study. Lancet 356 297-302 (2000).
49. Nosten, F. et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J. Infect. Dis. 170, 971-977 (1994).
50. Jansen, F. H. et al. Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis. Am. J. Trop. Med. Hyg. 77, 1005-1009 (2007).
51. Fitch, C. D. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 74, 1957-1972 (2004).
52. Hassan Alin, M., Bjorkman, A. & Wernsdorfer, W. H. Synergism of benflumetol and artemether in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 61, 439-445 (1999).
53. Ezzet, F., Mull, R. & Karbwang, J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br. J. Clin. Pharmacol. 46, 553-561 (1998).
54. Ezzet, F., van Vugt, M., Nosten, F., Looareesuwan, S. & White, N. J. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44, 697-704 (2000).
55. Checchi, F. et al. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: Pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar. J. 5, 59 (2006).
56. Bloland, P. B., Ettling, M. & Meek, S. Combination therapy for malaria in Africa: Hype or hope? Bull. World Health Organ. 78, 1378-1388 (2000).
57. Price, R. N. et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 42, 1570-1577 (2006).
58. Sisowath, C. et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J. Infect. Dis. 191, 1014-1017 (2005).
59. Dokomajilar, C., Nsobya, S. L., Greenhouse, B., Rosenthal, P. J. & Dorsey, G. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob. Agents Chemother. 50, 1893-1895 (2006).
60. Sisowath, C. et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop. Med. Int. Health 12, 736-742 (2007).
61. Sisowath, C. et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J. Infect. Dis. 199, 750-757 (2009).
62. Abdulla, S. et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: A randomised, single-blind, multicentre trial. Lancet 372, 1819-1827 (2008).
63. Naisbitt, D. J. et al. Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs. Chem. Res. Toxicol. 11, 1586-1595 (1998).
64. Olliaro, P. & Mussano, P. Amodiaquine for treating malaria. Cochrane Database Syst. Rev. 2003, CD000016 (2003).
65. Gasasira, A. F. et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin. Infect. Dis. 46, 985-991 (2008).
66. Pussard, E. et al. Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. Eur. J. Clin. Pharmacol. 33, 409-414 (1987).
67. White, N. J. et al. Pharmacokinetics of intravenous amodiaquine. Br. J. Clin. Pharmacol. 23, 127-135 (1987).
68. Legrand, E., Volney, B., Meynard, J. B., Mercereau-Puijalon, O. & Esterre, P. In vitro monitoring of Plasmodium falciparum drug resistance in French Guiana: A synopsis of continuous assessment from 1994 to 2005. Antimicrob. Agents Chemother. 52, 288-298 (2008).
69. de Dios, A. C., Casabianca, L. B., Kosar, A. & Roepe, P. D. Structure of the amodiaquine-FPIX mu oxo dimer solution complex at atomic resolution. Inorg. Chem. 43, 8078-8084 (2004).
70. Bray, P. G., Hawley, S. R., Mungthin, M. & Ward, S. A. Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum. Mol. Pharmacol. 50, 1559-1566 (1996).
71. Ochong, E. O., van den Broek, I. V., Keus, K. & Nzila, A. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am. J. Trop. Med. Hyg. 69, 184-187 (2003).
72. Holmgren, G. et al. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect. Genet. Evol. 6, 309-314 (2006).
73. Pradines, B. et al. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J. Clin. Microbiol. 44, 2404-2408 (2006).
74. Picot, S. et al. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar. J. 8, 89 (2009).
75. Faye, B. et al. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar. J. 6, 80 (2007).
76. Guthmann, J.-P. et al. High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. Am. J. Trop. Med. Hyg. 75, 143-145 (2006).
77. Hasugian, A. R. et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: Superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin. Infect. Dis. 44, 1067-1074 (2007).
78. Hien, T. T. et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363, 18-22 (2004).
79. Vennerstrom, J. L. et al. Bisquinolines. 1. N,N-bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria. J. Med. Chem. 35, 2129-2134 (1992).
80. Davis, T. M., Hung, T. Y., Sim, I. K., Karunajeewa, H. A. & Ilett, K. F. Piperaquine: A resurgent antimalarial drug. Drugs 65, 75-87 (2005).
81. Liu, C. et al. Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers. Yakugaku Zasshi 127, 1709-1714 (2007).
82. Ashley, E. A. et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin. Infect. Dis. 41, 425-432 (2005).
83. Smithuis, F. et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: An open-label randomised comparison. Lancet 367, 2075-2085 (2006).
84. Karunajeewa, H. et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br. J. Clin. Pharmacol. 57, 93-99 (2004).
85. Warhurst, D. C. & Duraisingh, M. T. Rational use of drugs against Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 95, 345-346 (2001).
86. Basco, L. K. & Ringwald, P. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob. Agents Chemother. 47, 1391-1394 (2003).
87. Muangnoicharoen, S., Johnson, D. J., Looareesuwan, S., Krudsood, S. & Ward, S. A. Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob. Agents Chemother. 53, 1362-1366 (2009).
88. Vivas, L. et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop. 105, 222-228 (2008).
89. Basco, L. K., Ringwald, P., Franetich, J. F. & Mazier, D. Assessment of pyronaridine activity in vivo and in vitro against the hepatic stages of malaria in laboratory mice. Trans. R. Soc. Trop. Med. Hyg. 93, 651-652 (1999).
90. Ringwald, P., Meche, F. S. & Basco, L. K. Short report: Effects of pyronaridine on gametocytes in patients with acute uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 61, 446-448 (1999).
91. Pagola, S., Stephens, P. W., Bohle, D. S., Kosar, A. D. & Madsen, S. K. The structure of malaria pigment β-haematin. Nature 404, 307-310 (2000).
92. Auparakkitanon, S., Chapoomram, S., Kuaha, K., Chirachariyavej, T. & Wilairat, P. Targeting of hematin by the antimalarial pyronaridine. Antimicrob. Agents Chemother. 50, 2197-2200 (2006).
93. Wu, L. J., Rabbege, J. R., Nagasawa, H., Jacobs, G. & Aikawa, M. Morphological effects of pyronaridine on malarial parasites. Am. J. Trop. Med. Hyg. 38, 30-36 (1988).
94. Chang, C., Lin-Hua, T. & Jantanavivat, C. Studies on a new antimalarial compound: Pyronaridine. Trans. R. Soc. Trop. Med. Hyg. 86, 7-10 (1992).
95. Ringwald, P., Bickii, J. & Basco, L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet 347, 24-28 (1996).
96. Basco, L. K. & Ringwald, P. Molecular epidemiology of malaria in Yaounde, Cameroon. VII. Analysis of recrudescence and reinfection in patients with uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 63, 215-221 (2000).
97. Ramharter, M. et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J. Infect. Dis. 198, 911-919 (2008).
98. Price, R. N. et al. Vivax malaria: Neglected and not benign. Am. J. Trop. Med. Hyg. 77, 79-87 (2007).
99. Ratcliff, A. et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: An open-label randomised comparison. Lancet 369, 757-765 (2007).
100. Tjitra, E. et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: A prospective study in Papua, Indonesia. PLoS Med. 5, e128 (2008).
101. Clark, R. L. et al. Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Res. B. Dev. Reprod. Toxicol. 71, 380-394 (2004).
102. Brewer, T. G., Genovese, R. F., Newman, D. B. & Li, Q. Factors relating to neurotoxicity of artemisinin antimalarial drugs "listening to arteether". Med. Trop. (Mars) 58, 22-27 (1998).
103. McGready, R. et al. Artemisinin antimalarials in pregnancy: A prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin. Infect. Dis. 33, 2009-2016 (2001).
104. Rijken, M. J. et al. Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: A preliminary report. Am. J. Trop. Med. Hyg. 78, 543-545 (2008).
105. White, N. J., McGready, R. M. & Nosten, F. H. New medicines for tropical diseases in pregnancy: Catch-22. PLoS Med. 5, e133 (2008).
106. WHO. World malaria report 2008 (WHO, Geneva, 2008).
107. Laufer, M. K., Djimde, A. A. & Plowe, C. V. Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am. J. Trop. Med. Hyg. 77, 160-169 (2007).
108. Vestergaard, L. S. & Ringwald, P. Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. Am. J. Trop. Med. Hyg. 77, 153-159 (2007).
109. Sibley, C. H., Barnes, K. I., Watkins, W. M. & Plowe, C. V. A network to monitor antimalarial drug resistance: A plan for moving forward. Trends Parasitol. 24, 43-48 (2008).
110. Newton, P. N. et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med. 5, e32 (2008).
111. Bate, R., Coticelli, P., Tren, R. & Attaran, A. Antimalarial drug quality in the most severely malarious parts of Africa - a six country study. PLoS ONE 3, e2132 (2008).
112. Fidock, D. A., Eastman, R. T., Ward, S. A. & Meshnick, S. R. Recent highlights in antimalarial drug resistance and chemotherapy research. Trends Parasitol. 24, 537-544 (2008).
113. Hay, S. I., Smith, D. L. & Snow, R. W. Measuring malaria endemicity from intense to interrupted transmission. Lancet Infect. Dis. 8, 369-378 (2008).
114. Moon, S., Perez Casas, C., Kindermans, J. M., de Smet, M. & von Schoen-Angerer, T. Focusing on quality patient care in the new global subsidy for malaria medicines. PLoS Med. 6, e1000106 (2009).
115. Hay, S. I., Rogers, D. J., Toomer, J. F. & Snow, R. W. Annual Plasmodium falciparum entomological inoculation rates (EIR) across Africa: Literature survey, internet access and review. Trans. R. Soc. Trop. Med. Hyg. 94, 113-127 (2000).
116. Smith, D. L., Dushoff, J. & McKenzie, F. E. The risk of a mosquito-borne infection in a heterogeneous environment. PLoS Biol. 2, e368 (2004).
117. Coluzzi, M. The clay feet of the malaria giant and its African roots: hypotheses and inferences about origin, spread and control of Plasmodium falciparum. Parassitologia 41, 277-283 (1999).
118. Obsomer, V., Defourny, P. & Coosemans, M. The Anopheles dirus complex: Spatial distribution and environmental drivers. Malar. J. 6, 26 (2007).
119. Struik, S. S. & Riley, E. M. Does malaria suffer from lack of memory? Immunol. Rev. 201, 268-290 (2004).
120. Breman, J. G., Alilio, M. S. & Mills, A. Conquering the intolerable burden of malaria: WhAt's new, what's needed: a summary. Am. J. Trop. Med. Hyg. 71, 1-15 (2004).
121. Hastings, I. M. & Watkins, W. M. Intensity of malaria transmission and the evolution of drug resistance. Acta Trop. 94, 218-229 (2005).
122. Williams, T. N. Human red blood cell polymorphisms and malaria. Curr. Opin. Microbiol. 9, 388-394 (2006).
123. Rogerson, S. J., Hviid, L., Duffy, P. E., Leke, R. F. & Taylor, D. W. Malaria in pregnancy: Pathogenesis and immunity. Lancet Infect. Dis. 7, 105-117 (2007).
124. Langhorne, J., Ndungu, F. M., Sponaas, A. M. & Marsh, K. Immunity to malaria: More questions than answers. Nature Immunol. 9, 725-732 (2008).
125. Fidock, D. A. et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6, 861-871 (2000).
126. Djimde, A. et al. A molecular marker for chloroquineresistant falciparum malaria. N. Engl. J. Med. 344, 257-263 (2001).
127. Laufer, M. K. et al. Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med. 355, 1959-1966 (2006).
128. Mita, T. et al. Expansion of wild type allele rather than back mutation in pfcrt explains the recent recovery of chloroquine sensitivity of Plasmodium falciparum in Malawi. Mol. Biochem. Parasitol. 135, 159-163 (2004).
129. Ginsburg, H. Should chloroquine be laid to rest? Acta Trop. 96 16-23 (2005).
130. Sowunmi, A., Adedeji, A. A., Gbotosho, G. O., Fateye, B. A. & Happi, T. C. Effects of pyrimethamine-sulphadoxine, chloroquine plus chlorpheniramine, and amodiaquine plus pyrimethamine-sulphadoxine on gametocytes during and after treatment of acute, uncomplicated malaria in children. Mem. Inst. Oswaldo Cruz 101, 887-893 (2006).
131. Ogungbamigbe, T., Ojurongbe, O., Ogunro, P., Okanlawon, B. & Kolawole, S. Chloroquine resistant Plasmodium falciparum malaria in Osogbo Nigeria: Efficacy of amodiaquine + sulfadoxinepyrimethamine and chloroquine + chlorpheniramine for treatment. Mem. Inst. Oswaldo Cruz 103, 79-84 (2008).
132. Sadasivaiah, S., Tozan, Y. & Breman, J. G. Dichlorodiphenyltrichloroethane (DDT) for indoor residual spraying in Africa: How can it be used for malaria control? Am. J. Trop. Med. Hyg. 77, 249-263 (2007).
133. Guyatt, H. L. & Snow, R. W. Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa. Trans. R. Soc. Trop. Med. Hyg. 95, 569-576 (2001).
134. Steketee, R. W., Nahlen, B. L., Parise, M. E. & Menendez, C. The burden of malaria in pregnancy in malaria-endemic areas. Am. J. Trop. Med. Hyg. 64, 28-35 (2001).
135. ter Kuile, F. O., van Eijk, A. M. & Filler, S. J. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: A systematic review. JAMA 297, 2603-2616 (2007).
136. Schellenberg, D. et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: A randomised, placebo-controlled trial. Lancet 357, 1471-1477 (2001).
137. Macete, E. et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: A randomized, placebo-controlled trial. J. Infect. Dis. 194, 276-285 (2006).
138. Kobbe, R. et al. Malaria incidence and efficacy of intermittent preventive treatment in infants (IPTi). Malar. J. 6, 163 (2007).
139. White, N. J. How antimalarial drug resistance affects post-treatment prophylaxis. Malar. J. 7, 9 (2008).
140. UNICEF. Malaria and children: Progress in intervention coverage (UNICEF, New York, 2007).